Principal Investigators

    Professor Peter Passmore


    Queen's University Belfast

    Contact information of lead PI


    United Kingdom

    Title of project or programme

    ‘A randomized controlled trial of calcium channel blockade (CCB) with amlodipine for the treatment of subcortical ischaemic vascular dementia (SIVD)’. (AFFECT clinical trial).

    Source of funding information

    Alzheimer's Society

    Total sum awarded (Euro)

    € 1,529,167

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Alzheimer's disease & other dementias


    Research Abstract

    Vascular dementia (VaD) is a highly significant health issue, affecting millions of people worldwide, and
    presenting a substantial challenge and burden for health service provision, health economics and informal
    and formal care. Despite this there are no effective pharmacological treatments. Developing new, effective
    treatments is therefore an urgent imperative to ensure this enormous unmet need is addressed. Currently
    this is not being fulfilled by any ongoing research.
    SIVD is the most common type of VaD. It is a progressive condition, with many patients with SIVD
    showing hypertension and hypercholesterolaemia in addition to other cardiovascular comorbidities. It is
    increasingly the most important form of VaD, yet there is only one currently registered pharmacological
    treatment trial for SIVD.
    This study will compare the effectiveness of active intervention involving use of the calcium channel
    blocking medication (CCB) amlodipine to placebo in 588 people with SIVD in a double blind, randomised
    controlled trial (RCT). The use of amlodipine is based on convincing data for the potential value of the
    CCB drug class and the need for further elucidation of their efficacy.
    This study will provide valuable evidence regarding the efficacy of amlodipine treatment on cognition in
    people with SIVD, in addition to secondary outcome measures including overall function, neuropsychiatric
    symptoms, carer burden and cost-effectiveness. The outcomes therefore have the potential to influence
    prescribing practice and result in improved treatment for people with SIVD.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: United Kingdom
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF